Licensing of E-58425 for Acute Pain to Mundipharma International GmbH
PharmaVentures Advises ESTEVE in Its pharma licensing Deal for E-58425, a New Therapeutic Product for Pain.
For press enquiries, please contact:
Senior Marketing Manager
+44 (0) 1865 332700
OXFORD, UK, January 13th, 2015
PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful license agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.
ESTEVE is a privately-held pharmaceutical and chemical group that focuses on innovation and excellence in health. In a Phase II clinical study in post-operative pain, E-58425 demonstrated significant superior efficacy and safety compared to a standard of care.
Adrian Dawkes, Vice President, PharmaVentures Ltd. who was lead advisor to ESTEVE commented: “We are delighted to have worked with ESTEVE in partnering E-58425 which represents a great step forward in the pain sector.”
Fintan Walton, Chief Executive, PharmaVentures, Ltd added: “We continue to be recognised as a strong leader in healthcare deal making and this adds to a growing list of our recent successes”.
For the past 23 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.